CBIO

Crescent Biopharma, Inc. Common Stock
CBIO

Overview Fund Activity

49 hedge funds and large institutions have $52.1M invested in Crescent Biopharma, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 11 closing their positions.

Holders
49
Holders Change
-6
Holders Change %
-10.91%
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
18
Closed
11
Calls
$389K
Puts
$31K
Net Calls
+$358K
Net Calls Change
+$231K

Top Buyers

1
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.63M
2
GCP
2
GSA Capital Partners
United Kingdom
$141K
3
Renaissance Technologies
3
Renaissance Technologies
New York
$302K
4
BCM
4
Bridgeway Capital Management
Texas
$258K
5
ACP
5
Acuta Capital Partners
California
$41.3K

Top Sellers

1
Acadian Asset Management
1
Acadian Asset Management
Massachusetts
$1.27M
2
Two Sigma Advisers
2
Two Sigma Advisers
New York
$329K
3
Marshall Wace
3
Marshall Wace
United Kingdom
$0
4
Truist Financial
4
Truist Financial
North Carolina
$0
5
Two Sigma Investments
5
Two Sigma Investments
New York
$171K
Name Market Value Shares Shares
Change 		Shares
Change %
Susquehanna International Group
51
Susquehanna International Group
Pennsylvania
– – -42,069 Closed
SWP
52
Stratos Wealth Partners
Ohio
– – -33,340 Closed
Simplex Trading
53
Simplex Trading
Illinois
– – -18,340 Closed
TSS
54
Two Sigma Securities
New York
– – -10,984 Closed
UBS Group
55
UBS Group
Switzerland
– – -6,323 Closed
Citadel Advisors
56
Citadel Advisors
Florida
– – -2,062 Closed
IPW
57
Impact Partnership Wealth
Georgia
– – -575 Closed
CWC
58
Carolinas Wealth Consulting
North Carolina
– – -395 Closed
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
– – -167 Closed
CFGS
60
Concourse Financial Group Securities
Alabama
– – – –
Barclays
61
Barclays
United Kingdom
$0 152 +76 +100%
1 2
3